원문 보기
Uh, well, we're fully invested and we're very comfortable being fully invested. Kathy Wood just made a quiet move that could signal something much bigger beneath the surface. In just a few trading days, the Arc Invest founder poured more than $1.3 million into a single speculative healthcare stock, doubling down on a technology many investors still struggle to understand.
This wasn't about hype or headlines. This was about conviction. The stock at the center of this move is Crisper Therapeutics, a gene editing company that sits at the heart of Cathy Wood's long-term vision for transformational innovation. While Arc Invest's daily trades often grab attention, this purchase was anything but sudden.
Across all ARK ETFs combined, Crisper now accounts for nearly 3.8% of total assets, showing that this is a long-term bet, not a short-term trade. On Friday, December 26, ARK acquired more than 23,000 shares of Crisper Therapeutics, spending over $1.3 million in a single day. Nearly 20,000 shares went into ARK, while the rest were added to ARC G.
But this was only the latest chapter in an aggressive buying spree. Earlier that same week, ARK purchased more than 43,000 shares on Tuesday for roughly $2.5 million. On Wednesday, it added another 10,000 shares worth nearly $600,000. In total, Kathy Wood loaded up on more than 76,800 shares of Crisper in just three trading days, sending a clear message about her confidence in the company's future.
Crisper technology works like a word processor for DNA. Scientists use a guide RNA to locate a specific genetic sequence and an enzyme then cuts it, allowing faulty genetic code to be repaired or rewritten. For diseases caused by a single defective gene, this approach could fix the problem at its core rather than simply treating symptoms.
That's why Kathy Wood views gene editing as a foundational technology, not just another biotech trend. Still, Crisper Therapeutics remains a controversial investment. The company sits in an uncomfortable middle ground. Not fully pre-revenue, but not yet meaningfully profitable either. In the first 9 months of 2025, it generated just $2.65 million in grant related revenue and reported no collaboration revenue at all, reinforcing concerns among more conservative investors.
However, the balance sheet tells a very different story. Crisper Therapeutics is sitting on nearly $1.9 billion in cash, giving it substantial financial runway and reducing the risk of near-term dilution. This allows the company to continue funding research, clinical trials, and commercialization without immediate pressure to raise capital.
The market has already priced in a great deal of optimism. Since its IPO in 2016 at $14 per share, Crisper stock has climbed to around $55, valuing the company at roughly $5.3 billion. While that's still far below its pandemic era peak of over $210, the stock is up about 40% in 2025 alone, easily outperforming the broader market.
The company's most important milestone came in December 2023 when its gene editing therapy Excel also known as Caskegevi received FDA approval. This marked the first time a crisper cast 9based treatment moved from theory into real world medicine. The therapy targets cickle cell disease and transfusion dependent betthalmia, two serious genetic disorders with limited treatment options.
Under its partnership with Vertex Pharmaceuticals, Vert.Ex Ex leads global development, manufacturing, and commercialization. While costs and profits are split 60/40, this structure allows Crisper to benefit from largecale execution without carrying the full operational burden, significantly improving its long-term risk profile.
Kathy Wood doesn't see Crisper as a single product company. She sees it as a toolbox capable of serving multiple massive markets including genetic diseases, cancer and immune cell therapies, cardioabolic conditions, and diagnostic tools. Each of these markets represents a multi-billion dollar opportunity on its own.
Industry estimates suggest the genome editing market could grow from under $10 billion in 2024 to nearly $23 billion by 2032. Analysts expect Crisper Therapeutics revenue to scale rapidly, potentially reaching hundreds of millions within a few years and climbing into the billions by the end of the decade if execution meets expectations.
Kathy Wood often compares gene editing today to the internet in the 1990s. Early, volatile, and misunderstood, but ultimately capable of reshaping entire industries. For her, genomics is not just about healthcare. It's about changing how diseases are treated at a fundamental level. As she has said before, she believes the next generation of fang style companies could emerge from the gene editing space.
And with this latest multi-million dollar buying spree, Kathy Wood is making it clear that she believes Crisper Therapeutics could be one of
Comments 0